Table 1. Summary of Baseline Characteristics Comparing Patients Receiving Tenofovir vs Entecavir Before and After Propensity Score Matching.
| Characteristic | No. of studies | Tenofovir cohort | Entecavir cohort | P valuea | ||
|---|---|---|---|---|---|---|
| Total No. of patients | Value (95% CI) | Total No. of patients | Value (95% CI) | |||
| Before propensity score matching | ||||||
| Age, mean, y | 12 | 11 415 | 48.90 (46.75-51.04) | 47 813 | 51.48 (49.41-53.55) | .09 |
| Sex, % | ||||||
| Women | 12 | 11 415 | 34.87 (31.82-38.05) | 47 813 | 34.75 (32.08-37.52) | .95 |
| Men | 12 | 11 415 | 65.13 (61.94-68.18) | 47 813 | 65.25 (62.48-67.92) | |
| Mean BMI | 6 | 6087 | 23.93 (23.13-24.74) | 14 851 | 23.94 (23.13-24.75) | .99 |
| Type 2 diabetes, % | 12 | 11 415 | 9.70 (7.62-12.27) | 47 813 | 13.20 (10.39-16.63) | .07 |
| Cirrhosis, % | 12 | 11 415 | 63.92 (27.78-89.08) | 47 813 | 51.52 (18.79-82.99) | .64 |
| Decompensated cirrhosis, % | 3 | 7094 | 10.82 (7.11-16.12) | 3274 | 14.11 (7.82-24.13) | .46 |
| HBeAg postive, % | 12 | 11 415 | 46.76 (37.32-56.44) | 47 813 | 41.68 (31.44-52.69) | .49 |
| HBV DNA, mean log IU/mL | 11 | 11 199 | 5.56 (4.95-6.17) | 47 135 | 5.85 (5.30-6.40) | .49 |
| ALT level, mean, U/L | 7 | 5567 | 121.23 (90.74-151.72) | 11 266 | 134.77 (108.45-161.10) | .51 |
| After propensity score matching | ||||||
| Age, mean, y | 14 | 10 420 | 49.70 (47.64-51.74) | 13 969 | 50.01 (47.73-52.29) | .84 |
| Sex, % | ||||||
| Women | 14 | 10 420 | 33.21 (26.46-40.73) | 13 969 | 32.42 (24.83-41.05) | .89 |
| Men | 14 | 10 420 | 64.88 (55.99-72.85) | 13 969 | 65.22 (55.66-73.69) | .91 |
| Mean BMI | 7 | 6657 | 24.49 (23.15-25.82) | 9921 | 24.56 (23.29-25.82) | .94 |
| Type 2 diabetes, % | 13 | 10 542 | 10.80 (8.34-13.87) | 13 808 | 10.72 (8.31-13.72) | .97 |
| Cirrhosis, % | 14 | 10 420 | 50.68 (20.57-80.31) | 13 969 | 55.19 (20.69-85.33) | .86 |
| Decompensated cirrhosis, % | 4 | 4885 | 10.41 (7.17-14.87) | 3233 | 8.66 (5.47-13.46) | .53 |
| HBeAg positive, % | 13 | 10 542 | 43.51 (34.85-52.58) | 13 808 | 42.48 (32.58-53.03) | .88 |
| HBV DNA, mean log IU/mL | 10 | 7639 | 5.90 (5.50-6.30) | 7702 | 5.90 (5.49-6.31) | >.99 |
| ALT level, mean U/L | 7 | 4216) | 125.77 (105.32-146.22) | 4666 | 124.89 (106.45-143.33) | .95 |
Abbreviations: ALT, alanine transaminase; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); HBeAg, hepatitis Be antigen; HBV, hepatitis B virus.
SI conversion factor: To convert ALT to μkat/L, multiply by 0.0167.
a
Comparison of baseline characteristics between patients receiving tenofovir and patients receiving entecavir.